Join our daily newsletter At The Bell to receive exclusive market insights
- AusCann Group (AC8) begins designing a clinical discovery trial to evaluate its cannabinoid-based formulation in people with spinal cord injury (SCI)
- Spinal cord injury occurs when there is damage to any part of the spinal cord or nerves at the end of the spinal cord
- Data from the trial may be used to support a more extensive human drug development program for marketing approval via the US Food and Drug Administration
- The trial will begin once approval is received by the human research ethics committee (HREC) with a submission expected to be made early next year
- AusCann is up 5.26 per cent on the market with shares trading at 10 cents
AusCann Group (AC8) has begun designing a clinical discovery trial to evaluate its cannabinoid-based formulation in people with spinal cord injury (SCI).
Spinal cord injury occurs when there is damage to any part of the spinal cord or nerves at the end of the spinal cord. This may occur when a sudden blow or cut to the spine occurs.
People with a SCI often experience a permanent loss of strength, sensation and function below the site of the injury.
Current treatment includes supportive care, medication, surgery or therapy.
This trial follows the completion of a technical assessment for the use of cannabinoids associated with SCI.
The overall aim is to generate clinical data on the benefits of AusCann’s cannabinoid-based formulations for people suffering from SCI.
The data may then be used to support a more extensive human drug development program for marketing approval via the US Food and Drug Administration.
The trial will begin once approval is received by the human research ethics committee (HREC) with a submission expected to be made early next year.
Additionally, the trial will be led by renowned pain specialist Dr Marc Russo.
Upon completion of the trial, AusCann will withdraw from its investigator-led trial to redirect its resource to a research and development program to support product registration in targeted medical conditions.
AusCann was up 5.26 per cent on the market with shares trading at 10 cents at 12:34 pm AEDT.
